




SCYNEXIS, Inc.  
Investor Relations Department  
3501 C Tricenter Boulevard  
Durham, NC 27713  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#) 

**NASDAQ: SCYX**

Last Trade:	1.91
Trade Time:	4:00 PM ET Jun 23, 2017
Change:	-0.01  (-0.521%)
Day Range	1.86 - 2.01
52-Week Range	1.55 - 5.51
Volume	410,541

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

SCYNEXIS, Inc. is a drug development company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapeutic areas.

We are developing our lead product candidate, SCY-078, as a novel and structurally distinct triterpenoid glucan synthase inhibitor. [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Jun 15, 2017*

[New Study Further Demonstrates In Vitro Activity of SCYNEXIS' Lead Anti-Infective Candidate, SCY-078, Against Drug-Resistant Candida Fungal Strains](#)

*Jun 13, 2017*

[SCYNEXIS, Inc. to Participate in the 2017 BIO International Convention](#)

*Jun 5, 2017*

[Eight Presentations at ASM Microbe 2017 Further Highlight the Strong Antifungal Effect and Promising Safety Profile of Lead Anti-Infective Candidate SCY-078](#)

*May 24, 2017*

[Eight SCY-078 Data Presentations at ASM Microbe 2017 Confirm Potential of SCYNEXIS' Lead Agent to Combat Serious and Life-threatening Fungal Infections](#)

*May 11, 2017*

[Potent in vitro Activity of SCYNEXIS' SCY-078 Against Multidrug-Resistant Fungal Pathogen Candida auris Further Confirmed in an in vitro Study Conducted by the Centers for Disease Control and Prevention \(CDC\)](#)

## Financials [\[ View all \]](#)

[First Quarter Financial Results](#)

*Mar 13, 2017*

[Annual Report \(10-K\)](#)

*Apr 26, 2017*

[Proxy Statement \(DEF 14A\)](#)

*May 8, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 7, 2016*

[Quarterly Report \(10-Q\)](#)

*Aug 8, 2016*

[Quarterly Report \(10-Q\)](#)